Breaking News, Trials & Filings

Touchlight Cleared by FDA for IND Utilizing Doggybone DNA

Major landmark demonstrates the clinical adoption of Touchlight's proprietary technology across modalities.

Touchlight Genetics Ltd., a Contract Development and Management Organization (CDMO) pioneering enzymatic DNA production to enable genetic medicines, announced the first FDA clearance of an Investigational New Drug (IND) application using doggybone DNA (dbDNA). Within the trial, planned by one of Touchlight’s clients, dbDNA will be used as an in vitro transcription template for mRNA production in the manufacturing of a cell therapy product. According to Touchlight, the trial sponsor has ope...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters